Kissei Partners with Reborna for Rare Disease Therapies

Kissei Pharmaceutical Co (JP:4547) has released an update.

Kissei Pharmaceutical Co. has entered into a research collaboration with Reborna Biosciences to develop treatments for genetic rare diseases, using Reborna’s RNA-targeting technology. Kissei will handle development and commercialization, providing payments including milestones and royalties to Reborna. This partnership aims to leverage both companies’ strengths to address challenges in rare disease drug discovery.

For further insights into JP:4547 stock, check out TipRanks’ Stock Analysis page.